Rat Anti-Mouse CD80
- Known as:
- Rat Antibody toMouse CD80
- Catalog number:
- 128-10053-1
- Product Quantity:
- 500
- Category:
- -
- Supplier:
- Ray Biotech
- Gene target:
- Rat Anti-Mouse CD80
Related genes to: Rat Anti-Mouse CD80
- Gene:
- CD80 NIH gene
- Name:
- CD80 molecule
- Previous symbol:
- CD28LG, CD28LG1
- Synonyms:
- B7.1, B7-1
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-14
- Date modifiied:
- 2016-10-05
Related products to: Rat Anti-Mouse CD80
Related articles to: Rat Anti-Mouse CD80
- Peptide cancer vaccines often suffer from poor lymphatic drainage, limited antigen-presenting cell uptake, and weak innate immune activation. To overcome these barriers, we engineered the Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) platform, which covalently links neoantigen epitopes to the TLR7 agonist 1V209 through site-selective lysine conjugation. Synthesized by Fmoc solid-phase peptide synthesis, SaPAC conjugates self-assemble into cationic nanoparticles with hydrodynamic diameters of approximately 100-200 nm. Compared with unconjugated self-assembling peptide nanoparticles mixed with soluble adjuvant, SaPAC nanoparticles enhanced lymphatic drainage and antigen persistence in draining lymph nodes. Mechanistically, SaPAC activated the TLR7-MyD88 axis, promoted plasmacytoid dendritic cell and macrophage recruitment, drove APC maturation (CD80CD86), and enhanced MHC-I cross-presentation to amplify antigen-specific CD8+ T-cell priming. Therapeutically, SaPAC monotherapy suppressed tumor growth in B16-OVA melanoma and MB49 bladder carcinoma models by increasing intratumoral infiltration of activated CD8+ T cells and NK cells. In an orthotopic 4T1 triple-negative breast cancer model, multivalent SaPAC vaccination synergized with anti-PD-1 blockade and achieved durable tumor suppression comparable to the Poly(I:C)-adjuvanted benchmark without detectable systemic toxicity. Collectively, SaPAC represents a chemically defined platform that bridges innate and adaptive anti-tumor immunity. - Source: PubMed
Publication date: 2026/10/02
Wu Yang-FanHu Jing-ChuHu Ye-FanLi Wen-JunRong LiLi Ren-HaoYao YuanHu LehanWang Xiao-LeiZhang Bao-ZhongLu YichengChow Shing-FungSu CanhuiYau ThomasChung Clive Yik-ShamHuang Jian-Dong - The extracellular matrix-mimetic performance of hydrogel micropores makes them promising delivery carriers for dendritic cell (DC) vaccines. Nevertheless, the reported hydrogel failed to decouple the intricate relationship between pore size and mechanical performance, thus the regulatory effect of pore size on DCs immune function remains inadequately understood. In this study, we constructed a supramolecular hydrogel system in which pore size was decoupled from mechanical performance using a sacrificial gelatin microgel template and synergetic photopolymerization. The effects of hydrogel pore size on the immune function of immature bone marrow-derived dendritic cells (BMDCs) were investigated. Results showed that hydrogels with 15-μm pore-size significantly promoted BMDC migration and release; upregulated the expression of costimulatory molecules CD80, CD86, CD40 and major histocompatibility complex class II molecules; promoted the secretion of proinflammatory cytokines; and inhibited the expression of anti-inflammatory cytokines. In addition, BMDCs regulated by the 15-μm pore-size hydrogel promoted the differentiation of CD8 effector T cells and inhibited the differentiation of CD8 exhausted T cells and regulatory T cells. Thus, in supramolecular hydrogels, pore size acts as a biophysical cue for the immunomodulation of BMDCs. Our findings provide an experimental basis for improving the antitumor effect of DC vaccines. - Source: PubMed
Publication date: 2026/10/02
Zhang HonghongWu CuifangTeng LijingSun XiaominXu PuZeng XianlinLong JinhuaZeng Zhu - Bacillus Calmette-Guérin (BCG) remains the only licensed vaccine for tuberculosis (TB), yet its efficacy wanes over time due to insufficient durability of vaccine-induced immunity. However, mechanisms constraining BCG vaccine-induced dendritic cell (DC)-mediated T cell priming are poorly understood. Cholesterol 25-hydroxylase (CH25H) converts cholesterol into 25-hydroxycholesterol (25-HC) that modulates antigen-presenting cell imprinting and innate immune responses. Here, we investigated whether CH25H regulates DC function and vaccine-induced protective immunity against (Mtb). We found that CH25H deficiency enhanced DC activation, characterized by increased expression of the costimulatory molecules CD80 and CD86, elevated interleukin (IL)-12p70 production, and reduced IL-10 secretion, resulting in augmented T cell proliferation and robust Th1 cytokine responses. Transcriptomic analyses of CH25H-deficient and 25-HC-treated DCs showed that an SREBP2-associated program may contribute to expression. BCG vaccination conferred enhanced protection in mice, including reduced Mtb burden and pulmonary inflammation. BCG-vaccinated mice developed more durable protective immunity and increased frequencies of CD103CD69 tissue-resident memory T cells, along with sustained IL-2-producing T cell responses. Collectively, these findings identify CH25H as a negative regulator of DC-mediated Th1 immunity and suggest that targeting CH25H represents a potential host-directed immunomodulatory strategy to enhance the long-term protective immunity of TB vaccination. - Source: PubMed
Publication date: 2026/09/30
Kim HagyuChoi EunsolKwon Kee WoongChoi Hong-HeeKim KyungminJung WeonSeokShin Sung Jae - Δ-Tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, has been reported to modulate immune responses; however, its effects on complex innate immune signaling pathways and inflammation remain incompletely understood. Here, we investigated the immunomodulatory effects of THC on lipopolysaccharide (LPS)-induced inflammation across cellular and models. - Source: PubMed
Publication date: 2026/09/16
Tomer ShalluHarding JeffreyWang LiKedia NanditaCook EthanLe VincentPlatt ChristopherLe JonathanTien NicholasPatalay KanishkhLangfelder PeterYang X WilliamZhang YeZhen Anjie - Cancer immunotherapy has shown considerable promise, particularly through dendritic cell (DC)-based vaccines, which are capable of inducing potent, durable, and tumor-specific immune responses. However, their clinical efficacy remains limited by the immature phenotype of DCs, inefficient antigen presentation, and the immunosuppressive tumor microenvironment. - Source: PubMed
Publication date: 2026/09/24
Eteghadi AtefehTaghipour NiloofarHosseinzadeh SimzarHashemi Seyed MahmoudGhasemi Fatemeh SadatSoleimani Masoud